The study objective was to evaluate meropenem population pharmacokinetics and
pharmacodynamics in nonobese, obese, and morbidly obese patients. Forty adult patients …

The study objective was to evaluate meropenem pharmacokinetics and pharmacodynamics
in morbid obesity. Nine patients hospitalized in an intensive care unit with a body mass …

Background and Objectives A quantitative evaluation of the PK of meropenem, a broad-
spectrum β-lactam antibiotic, in plasma and interstitial space fluid (ISF) of subcutaneous …

Meropenem serves as a clinically important, broad-spectrum antibiotic. While meropenem is
commonly used in obese patients, its pharmacokinetics in this patient group is not well …

Background Meropenem is an anti-Gram-negative antimicrobial, the time-dependent activity
of which may be maximized through administration by continuous infusion. Objectives The …

Study Objective. To assess the pharmacokinetics of meropenem administered as a 3‐hour
infusion. Design. Randomized, crossover, open‐label study. Setting. Clinical research …

The objectives of this study were to develop a meropenem population pharmacokinetic
model using patient data and use it to explore alternative dosage regimens that could …

Study Objective. To compare outcomes and cost for the traditional United States Food and
Drug Administration‐approved dosing regimen for meropenem versus an alternative dosing …

Severe pathophysiological changes in critical illness can lead to dramatically altered
antimicrobial pharmacokinetics (PK). The additional effect of obesity on PK potentially …

The economic benefit of a meropenem dosage strategy based on pharmacodynamic
concepts is described. The pharmacodynamics of novel meropenem dosing regimens were …